Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019 ...

Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

Novartis’ results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its ...

Novartis's product lineup is anchored by several key growth drivers, including Cosentyx, Pluvicto, Kisqali, and Scemblix. These products are expected to play a crucial role in achieving the ...

Novartis AG (NVS) reports robust financial performance with significant product sales growth, while addressing potential ...

FRANKFURT, Jan 31 (Reuters) - Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer ...